More on 9688
News
- Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
- Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
- Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
- Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRA
- Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint
- Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me
- Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
- Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
- Zai Lab Announces Participation in March Investor Conference
- Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
Entities mentioned with 9688
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Goldman Sachs | View Related Stories »
- Jefferies & Co | View Related Stories »
- PDUFA | View Related Stories »
- JPMorgan | View Related Stories »
- Citi | View Related Stories »
- Show More...
